{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:38:42Z","timestamp":1792809522818,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40273-026-01642-z","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:48:30Z","timestamp":1784119710000},"page":"1383-1395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhaled Levodopa for the Management of OFF Episodes in Parkinson\u2019s Disease: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Daniel","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushab","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Guerra-Primo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne C","family":"Gadeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Perni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Alexander","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubong","family":"Silas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira A. Parkinson disease. Eur J Neurol. 2020;27:27\u201342.","journal-title":"Eur J Neurol"},{"key":"1642_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70368","author":"SE Gandhi","year":"2025","unstructured":"Gandhi SE, et al. Comparative analysis of the incidence, prevalence, and survival of 8 types of parkinsonism in a population\u2010based study with 367 million person years of observation over 21 years. Mov Disord Clin Pract. 2025. https:\/\/doi.org\/10.1002\/mdc3.70368.","journal-title":"Mov Disord Clin Pract"},{"key":"1642_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","volume":"15","author":"S von Campenhausen","year":"2005","unstructured":"von Campenhausen S, et al. Prevalence and incidence of Parkinson\u2019s disease in Europe. Eur Neuropsychopharmacol. 2005;15:473\u201390.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1642_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.17294\/2330-0698.1836","volume":"8","author":"S Mantri","year":"2021","unstructured":"Mantri S, et al. The experience of OFF periods in Parkinson\u2019s disease: descriptions, triggers, and alleviating factors. J Patient Cent Res Rev. 2021;8:232\u20138.","journal-title":"J Patient Cent Res Rev"},{"key":"1642_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20:224\u201330.","journal-title":"Mov Disord"},{"key":"1642_CR6","first-page":"S255","volume":"26","author":"C Tanner","year":"2020","unstructured":"Tanner C. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26:S255\u201364.","journal-title":"Am J Manag Care"},{"key":"1642_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.parkreldis.2020.07.003","volume":"78","author":"LP Prizer","year":"2020","unstructured":"Prizer LP, et al. The presence of a caregiver is associated with patient outcomes in patients with Parkinson\u2019s disease and atypical parkinsonisms. Parkinsonism Relat Disord. 2020;78:61\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02074-2","volume":"21","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Real-world assessment of the impact of \u2018OFF\u2019 episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States. BMC Neurol. 2021;21:46.","journal-title":"BMC Neurol"},{"key":"1642_CR9","unstructured":"Gumber, A. et al. Economic, social and financial cost of Parkinson\u2019s on individuals, carers and their families in the UK. https:\/\/www.shu.ac.uk\/research\/specialisms\/centre-for-health-and-social-care-research\/reports\/economic-social-and-financial-cost-of-parkinsons-on-individuals-carers-and-their-families (2017)."},{"key":"1642_CR10","first-page":"S265","volume":"26","author":"I Abeynayake","year":"2020","unstructured":"Abeynayake I, Tanner CM. The economic impact of OFF periods in Parkinson disease. Am J Manag Care. 2020;26:S265\u20139.","journal-title":"Am J Manag Care"},{"key":"1642_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3111\/13696998.2010.551164","volume":"14","author":"LJ Findley","year":"2011","unstructured":"Findley LJ, et al. The economic burden of advanced Parkinson\u2019s disease: an analysis of a UK patient dataset. J Med Econ. 2011;14:130\u20139.","journal-title":"J Med Econ"},{"key":"1642_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/13696998.2021.1913009","volume":"24","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Real-world assessment of \u201cOFF\u201d episode\u2013related healthcare resource utilization among patients with Parkinson\u2019s disease in the United States. J Med Econ. 2021;24:540\u20139.","journal-title":"J Med Econ"},{"key":"1642_CR13","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F. On-demand therapy for OFF episodes in Parkinson\u2019s disease. Mov Disord. 2021;36:2244\u201353.","journal-title":"Mov Disord"},{"key":"1642_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385.","journal-title":"Arch Neurol"},{"key":"1642_CR15","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2016.11.020","volume":"33","author":"M Rosa-Grilo","year":"2016","unstructured":"Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR. The efficacy of apomorphine \u2013 a non-motor perspective. Parkinsonism Relat Disord. 2016;33:S28\u201335.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105859","volume":"116","author":"E Camgrand","year":"2023","unstructured":"Camgrand E, et al. Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2023;116:105859.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR17","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1007\/s00415-024-12323-2","volume":"271","author":"J Kassubek","year":"2024","unstructured":"Kassubek J, et al. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson\u2019s disease complicated by OFF episodes: a phase 3, open-label study. J Neurol. 2024;271:3554\u201370.","journal-title":"J Neurol"},{"key":"1642_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749\u201359.","journal-title":"Lancet Neurol"},{"key":"1642_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WNF.0000000000000111","volume":"38","author":"M Nomoto","year":"2015","unstructured":"Nomoto M, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38:241\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"1642_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","volume":"13","author":"RF Pfeiffer","year":"2007","unstructured":"Pfeiffer RF, Gutmann L, Hull KL Jr., Bottini PB, Sherry JH. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13:93\u2013100.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36469\/jheor.2021.29488","volume":"8","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Cost-effectiveness of apomorphine sublingual film as an \u2018on-demand\u2019 treatment for \u2018OFF\u2019 episodes in patients with Parkinson\u2019s disease. J Health Econ Outcomes Res. 2021;8:82\u201392.","journal-title":"J Health Econ Outcomes Res"},{"key":"1642_CR22","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1111\/bcp.14086","volume":"85","author":"M Torti","year":"2019","unstructured":"Torti M, et al. Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar). Br J Clin Pharmacol. 2019;85:2605\u201313.","journal-title":"Br J Clin Pharmacol"},{"key":"1642_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2710.1988.tb00179.x","volume":"13","author":"AJ Bayer","year":"1988","unstructured":"Bayer AJ, Day JJ, Finucane P, Pathy MS. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. J Clin Pharm Ther. 1988;13:191\u20134.","journal-title":"J Clin Pharm Ther"},{"key":"1642_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood N, Jimenez-Shahed J. Effective management of \u201cOFF\u201d episodes in Parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. NDT Int. 2023;19:247\u201366.","journal-title":"NDT Int"},{"key":"1642_CR25","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/advances\/nmab060","volume":"12","author":"JT Boelens Keun","year":"2021","unstructured":"Boelens Keun JT, Arnoldussen IA, Vriend C, van de Rest O. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson\u2019s disease: a systematic review. Adv Nutr. 2021;12:2265\u201387.","journal-title":"Adv Nutr"},{"key":"1642_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"A Fasano","year":"2015","unstructured":"Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol. 2015;14:625\u201339.","journal-title":"Lancet Neurol"},{"key":"1642_CR27","unstructured":"Britannia Pharmaceuticals Limited. Summary of product characteristics: APO-go AMPOULES 10mg\/ml solution for injection or infusion. https:\/\/www.medicines.org.uk\/emc\/product\/2233\/smpc (2023)."},{"key":"1642_CR28","unstructured":"NHS North East and North Cumbria. Shared Care Protocol: apomorphine injection for patients within adult services with Parkinson\u2019s disease. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fntag.nhs.uk%2Fwp-content%2Fuploads%2F2025%2F05%2FNENC-SCG-apomorphine-injection-in-parkinson-v1.1-May-2025.docx&wdOrigin=BROWSELINK (2025)."},{"key":"1642_CR29","unstructured":"NHS Nottinghamshire Area Prescribing Committee. Management of Parkinson\u2019s disease (PD) with apomorphine information sheet. https:\/\/www.nottsapc.nhs.uk\/media\/u0raozsq\/parkinsons-disease-apomorphine-information-sheet.pdf (2023)."},{"key":"1642_CR30","unstructured":"Bedfordshire, Luton and Milton Keynes Integrated Care System. shared care prescribing guideline apomorphine in Parkinson\u2019s disease. https:\/\/medicines.bedfordshirelutonandmiltonkeynes.icb.nhs.uk\/wp-content\/uploads\/2020\/04\/BLMK-Apomorphine-SCG-December-2024-Final.pdf (2024)."},{"key":"1642_CR31","unstructured":"Sandwell and West Birmingham Hospitals NHS Trust. Apomorphine shared care guidelines for advanced Parkinson\u2019s disease. https:\/\/sandwellandwestbhamccgformulary.nhs.uk\/docs\/Apomorphine%20sheared%20care%20guidelines%20-%20agreed.pdf."},{"key":"1642_CR32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/mdc3.70074","volume":"12","author":"M Aubignat","year":"2025","unstructured":"Aubignat M, Khelifi F, Rascol O, the NS\u2010PARK\/FCRIN Network. Use of and barriers to subcutaneous apomorphine pen injections in Parkinson\u2019s disease: a survey by the French NS - PARK Network. Movement Disord Clin Pract. 2025;12:1211\u20133.","journal-title":"Movement Disord Clin Pract"},{"key":"1642_CR33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","volume":"19","author":"D Athanasopoulos","year":"2012","unstructured":"Athanasopoulos D, Tagaris GA, Karageorgiou CE. Subcutaneous apomorphine injections for advanced Parkinson\u2019s disease: a long-term follow-up. Eur J Neurol. 2012;19:655.","journal-title":"Eur J Neurol"},{"key":"1642_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/00023210-200822060-00005","volume":"22","author":"RM Trosch","year":"2008","unstructured":"Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for \u2018off\u2019 episodes in Parkinson\u2019s disease: a 6-month open-label study. CNS Drugs. 2008;22:519\u201327.","journal-title":"CNS Drugs"},{"key":"1642_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.parkreldis.2012.01.001","volume":"18","author":"WG Ondo","year":"2012","unstructured":"Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18:619\u201322.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/PPA.S301644","volume":"15","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Patient preferences for treating \u2018OFF\u2019 episodes in Parkinson\u2019s disease: a discrete choice experiment. Patient Prefer Adherence. 2021;15:1187\u201396.","journal-title":"Patient Prefer Adherence"},{"key":"1642_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8858","volume":"8","author":"MM Lipp","year":"2016","unstructured":"Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8:360ra136.","journal-title":"Sci Transl Med"},{"key":"1642_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145\u201354.","journal-title":"Lancet Neurol"},{"key":"1642_CR39","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual | 4 economic evaluation. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2 (2022)."},{"key":"1642_CR40","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual | 6 committee recommendations. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/committee-recommendations-2 (2026)."},{"key":"1642_CR41","unstructured":"National Institute for Health and Care Excellence. Foslevodopa\u2013foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms TA934. https:\/\/www.nice.org.uk\/guidance\/ta934\/ (2023)."},{"key":"1642_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-022-00284-0","volume":"8","author":"O Okunoye","year":"2022","unstructured":"Okunoye O, Marston L, Walters K, Schrag A. Change in the incidence of Parkinson\u2019s disease in a large UK primary care database. NPJ Parkinsons Dis. 2022;8:23.","journal-title":"NPJ Parkinsons Dis"},{"key":"1642_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13:509\u201318.","journal-title":"Value Health"},{"key":"1642_CR44","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jval.2025.09.161","volume":"28","author":"U Silas","year":"2025","unstructured":"Silas U, et al. CO59 comparative efficacy safety and discontinuation of inhaled levodopa for patients with Parkinson\u2019s disease: a network meta-analysis. Value Health. 2025;28:S53.","journal-title":"Value Health"},{"key":"1642_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200220090-00005","volume":"20","author":"CS Palmer","year":"2002","unstructured":"Palmer CS, Nuijten MJC, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson\u2019s disease with entacapone in the United States. Pharmacoeconomics. 2002;20:617\u201328.","journal-title":"Pharmacoeconomics"},{"key":"1642_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.14802\/jmd.25031","volume":"18","author":"HJ Chang","year":"2025","unstructured":"Chang HJ, et al. Efficacy of levodopa\/benserazide dispersible tablets on \u201cdelayed ON\u201d to the first morning dose in patients with Parkinson\u2019s disease with motor fluctuations: a multicenter, randomized, open-label, crossover trial. JMD. 2025;18:244\u201352.","journal-title":"JMD"},{"key":"1642_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2020.08.028","volume":"79","author":"JS Hui","year":"2020","unstructured":"Hui JS, et al. Open-label titration of apomorphine sublingual film in patients with Parkinson\u2019s disease and \u201cOFF\u201d episodes. Parkinsonism Relat Disord. 2020;79:110\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR48","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s13311-019-00751-2","volume":"16","author":"W Ondo","year":"2019","unstructured":"Ondo W, et al. ASENT 2019 Abstracts - Long-term safety and tolerability of apomorphine sublingual film in patients with Parkinson\u2019s disease and \u201cOFF\u201d episodes. Neurotherapeutics. 2019;16:912\u20139.","journal-title":"Neurotherapeutics"},{"key":"1642_CR49","unstructured":"Pahwa, R. et al. Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson\u2019s disease: results from a Phase 3 double-blind, placebo-controlled trial. in MDS Abstracts (2018)."},{"key":"1642_CR50","unstructured":"Alvarez, E. et al. The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson\u2019s disease patients (DYSCOVER study). Movement Disorders 34, (2019)."},{"key":"1642_CR51","unstructured":"Office for National Statistics. National life tables: UK. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables."},{"key":"1642_CR52","unstructured":"National Institute for Health and Care Excellence. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/ (2025)."},{"key":"1642_CR53","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33:905\u201318.","journal-title":"CNS Drugs"},{"key":"1642_CR54","unstructured":"Care and Outcomes Research Centre. Unit costs 2022-2027. https:\/\/research.kent.ac.uk\/corec\/unit-costs-2022-2027\/."},{"key":"1642_CR55","unstructured":"NHS England. National cost collection for the NHS. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/."},{"key":"1642_CR56","unstructured":"dm+d browser. https:\/\/dmd-browser.nhsbsa.nhs.uk\/."},{"key":"1642_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159340","volume":"11","author":"T Fundament","year":"2016","unstructured":"Fundament T, et al. Deep brain stimulation for Parkinson\u2019s disease with early motor complications: a UK cost-effectiveness analysis. PLoS ONE. 2016;11:e0159340.","journal-title":"PLoS ONE"},{"key":"1642_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40273-022-01132-y","volume":"40","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, et al. The cost effectiveness of levodopa-carbidopa intestinal gel in the treatment of advanced Parkinson\u2019s disease in England. Pharmacoeconomics. 2022;40:559\u201374.","journal-title":"Pharmacoeconomics"},{"key":"1642_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","volume":"261","author":"S Eggington","year":"2014","unstructured":"Eggington S, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease. J Neurol. 2014;261:106\u201316.","journal-title":"J Neurol"},{"key":"1642_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","volume":"22","author":"S Kalabina","year":"2019","unstructured":"Kalabina S, et al. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales. J Med Econ. 2019;22:215\u201325.","journal-title":"J Med Econ"},{"key":"1642_CR61","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11136-012-0231-6","volume":"22","author":"MK Young","year":"2013","unstructured":"Young MK, Ng S-K, Mellick G, Scuffham PA. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson\u2019s disease. Qual Life Res. 2013;22:1065\u201372.","journal-title":"Qual Life Res"},{"key":"1642_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12955-020-01299-y","volume":"18","author":"M Zahra","year":"2020","unstructured":"Zahra M, et al. Parkinson\u2019s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial. Health Qual Life Outcomes. 2020;18:49.","journal-title":"Health Qual Life Outcomes"},{"key":"1642_CR63","unstructured":"Office for National Statistics. Employee earnings in the UK. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/annualsurveyofhoursandearnings\/2025."},{"key":"1642_CR64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.WNF.0000236762.77913.C6","volume":"30","author":"F Stocchi","year":"2007","unstructured":"Stocchi F, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol. 2007;30:18\u201324.","journal-title":"Clin Neuropharmacol"},{"key":"1642_CR65","unstructured":"Medicines and Healthcare products Regulatory Agency. Apomorphine with domperidone: minimising risk of cardiac side effects. https:\/\/www.gov.uk\/drug-safety-update\/apomorphine-with-domperidone-minimising-risk-of-cardiac-side-effects (2016)."},{"key":"1642_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, et al. Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020;71:4\u201310.","journal-title":"Parkinsonism Relat Disord"},{"key":"1642_CR67","unstructured":"British National Formulary. Treatment summary - Parkinson\u2019s disease. https:\/\/bnf.nice.org.uk\/treatment-summaries\/parkinsons-disease\/ (2025)."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01642-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01642-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01642-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:02:44Z","timestamp":1792807364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01642-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01642-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was funded by Merz Therapeutics GmbH. DE, CM, HK, RS, LGP, HCG and SP received funding from Merz for this project. WC, JB, GP and US are employees of Merz. CC has received advisory, consulting or lecture fees from AbbVie, Bial, Britannia, Mission Therapeutics, Merz and Roche.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study conception and design: DE, LGP, SP, WC, JB, GP, US and CC; data analysis and investigation: DE, CM, HK, RS, LGP and SP; writing \u2013 original draft preparation: DE, HK and HCG; writing \u2013 review and editing: DE, CM, RS, LGP, HCG, SP, WC, JB, GP, US and CC; supervision: LGP, HCG, SP, GP, US and CC.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Most data supporting the findings of this study are available within the paper and its Supplementary Information. Remaining data that support the findings of this study are available from the authors upon reasonable request.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}